Join Our Team

Careers

Join Our Team

The successful clinical translation of new technologies to the clinic requires a wide range of expertise. Our multi-disciplinary group of more than 100 prostate cancer scientists, physicians, trainees and healthcare employees from five leading Alberta health research institutions are working with an international collaborative network to achieve our translational research goals – to make a meaningful impact on health policy and the outcomes of patients living with prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by developing and successfully translating to the clinic innovative tests that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer.

Submit Your Resume

  • Accepted file types: pdf, doc, rtf.
    .pdf, .doc, .rtf

Nanostics is pleased to announce the launch of clinical validation study

EDMONTON, June 4, 2019 /CNW/ – Nanostics Inc. is pleased to Announce the start of its key Clinical validation study. APCaRI is managing the study and recruitment has begun at Calgary’s Prostate Cancer Centre (PCC) and Edmonton’s Northern Alberta Urology Centre (NAUC). Recruitment of men from the Yukon Territories will follow.
The study will be conducted in partnership with DynaLIFE Medical Labs with co-principal investigators Dr. Eric Hyndman (PCC) and Dr. Adrian Fairey’s (NAUC).
Nanostics recognizes and is very grateful for the funding and support we received from the Bird Dogs from the beginning of this research and development journey. Nanostics also thanks funders for the clinical study including the Motorcycle Ride for Dad, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University Hospital Foundation Kaye Fund.

- Unknown